Coronary Heart Disease Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome An Analysis From the Early Glycoprotein IIb/IIIa Inhibition in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) Trial

Received March 31, 2010; accepted December 17, 2010. From the Duke Clinical Research Institute (T.Y.W., J.A.W., P.T., R.A.H., L.K.N.), Durham, NC; TIMI Study Group (R.P.G., E.B.), Brigham and Women’s Hospital, Boston, MA; Herzzentrum Ludwigshafen (U.Z.), Ludwigshafen, Germany; Institut de Cardiologie (G.M.), Pitié-Salpêtrière Hospital, Paris, France; Uppsala University Hospital (S.K.J.), Uppsala, Sweden; University Hospital Gasthuisberg and Leuven Coordinating Center (F.V.W.), Leuven, Belgium; University of Alberta (P.W.A.), Edmonton, Alberta, Canada; and the Duke Translational Medicine Institute (R.M.C.), Durham, NC. Guest Editor for this article was Eric R. Bates, MD. Correspondence to Tracy Y. Wang, MD, MHS, MSc, Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27705. E-mail [email protected] © 2011 American Heart Association, Inc.